Eikon Therapeutics was co-founded by UC Berkeley researchers, one of whom has already received a Nobel Prize for the underlying technology.

Eikon Therapeutics, a US-based drug discovery and development company co-founded by University of California (UC), Berkeley researchers, has completed a $517.8m series B round from investors including UC Investments. Insurance provider Harel Insurance took part in the round, as did T Rowe Price Associates, Canada Pension Plan Investment Board, EcoR1 Capital, StepStone Group, Soros Capital,…

The rest of this content is only accessible to Global Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.